Press Releases

Month Year

Month Year

Feb 9, 2022

FDA Awards QIDP Designation for Prevention of Chlamydia to Evofem Biosciences

-- Adds Five Years of Market Exclusivity on Approval --
Feb 8, 2022

Evofem Biosciences to Present at Aegis Virtual Conference on Wednesday, February 23, 2022
Jan 19, 2022

Evofem Biosciences Announces Record Net Sales and Phexxi Prescriptions in Q4 2021

Net product revenue more than doubled in the fourth quarter of 2021 vs. third quarter of 2021
Jan 12, 2022

Phexxi Access to Expand under New Government Guidance Stating Insurers Must Cover FDA-approved Contraceptives with No Out-of-Pocket Costs to Women
Jan 4, 2022

Evofem Biosciences to Present at H.C. Wainwright BioConnect Conference
Dec 16, 2021

Evofem Biosciences and Orion Biotechnology Launch Collaboration to Develop MPT Product Candidate to Include HIV Prevention
Dec 9, 2021

Evofem Biosciences Expects Record High Phexxi Prescriptions and Strong Net Revenue Growth in Fourth Quarter 2021
Dec 8, 2021

Evofem Biosciences to Adjourn Special Meeting of Stockholders on December 8, 2021

-- Meeting to Reconvene on December 15, 2021 --
Nov 30, 2021

Evofem Biosciences Announces Successful Type C Meeting with FDA for STI Prevention Product Candidate
Nov 22, 2021

Evofem Biosciences Successfully Extends Cumulative Net Sales Covenant Timing to June 30, 2023

Show per page